The 38 linked references in paper N. Tsareva A., Н. Царева А. (2017) “Идиопатическая легочная артериальная гипертензия: современный подход к диагностике и лекарственной терапии // Idiopathic pulmonary arterial hypertension: current approach to diagnosis and pharmacological treatment” / spz:neicon:pulmonology:y:2017:i:2:p:216-231

  1. GaliéN., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J.2009; 34 (6): 1219–1263. DOI: 10.1183/ 09031936. 00139009.
  2. Vachiery J.-L., Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension.Eur. Respir. Rev. 2012; 21 (126): 313–320. DOI: 10.1183/09059180. 00005412.
  3. Chemla D., Castelain V., HervéP. et al. Haemodynamic evaluation of pulmonary hypertension.Eur. Respir. J.2002; 20 (5): 1314–1331. DOI: 10.1183/09031936.02.00068002.
  4. Benza R.L., Miller D.P., Gomberg-Maitland M. et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122 (2): 164–172. DOI: 10.1161/CIRCULATIONAHA.109.898122.
  5. Badesch B.D., Champion H.C., Gomez-Sanchez M.A. et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.2009; 54 (30): S55–S56. DOI: 10.1016/ j.jacc.2009.04.011.
  6. Berger R.M., Beghetti M., Humpl T. et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012; 379 (9815): 537–546. DOI: 10.1016/S0140-6736(11) 61621-8.
  7. Trulock E., Edwards L., Taylor D. et al. Registry of the International Society for Heart and Lung Transplantation twenty fourth official adult lung and heart lung transplantation report 2007. J. Heart Lung Transplant.2007; 26 (8): 782–795. DOI: 10.1016/j.healun.2007.06.003.
  8. Stehlik J., Edwards L.B., Kucheryavaya A.Y. et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report–2010.J. Heart Lung Transplant.2010; 29 (10): 1089– 1103. DOI: 10.1016/j.healun.2010.08.007.
  9. Sitbon O., Morrell N.W. Pathways in pulmonary arterial hypertension: the future is here. Eur. Respir. Rev. 2012; 21 (126): 321–327. DOI: 10.1183/09059180.00004812.
  10. Solomon J.J., Olson A.L., Fischer A. et al. Scleroderma lung disease.Eur. Respir. Rev.2013; 22 (127): 6–19. DOI: 10.1183/ 09059180.00005512.
  11. Guazzi M., GaliéN. Pulmonary hypertension in left heart disease. Eur. Respir. Rev. 2012; 21 (126): 338–346. DOI: 10.1183/ 09059180.00004612.
  12. Diller G.P., Dimopoulos K., Okonko D. et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005; 112 (8): 828–835. DOI: 10.1161/CIRCULATIONAHA.104.529800.
  13. Peacock A.J., Murphy N.F., McMurray J.J.V. et al. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J.2007; 30 (1): 104–109. DOI: 10.1183/09031936. 0009 2306.
  14. GaliéN., Palazzini M., Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur. Heart J. 2010; 31 (1): 2080–2086. DOI: 10.1093/eurheartj/ehq152.
  15. Michelakis E.D. The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail. Rev. 2003; 8 (1): 5–21. DOI: 10.1023/A:1022150819223.
  16. Rubin L.J., Simonneau G., Badesch D. et al. The study of risk in pulmonary arterial hypertension.Eur. Respir. Rev. 2012; 21 (125): 234–238. DOI: 10.1183/09059180. 00003712.
  17. Humbert M., Souza R., Galie N. et al. Pulmonary arterial hypertension: bridging the present to the future.Eur. Respir. Rev.2012; 21 (126): 267–270. DOI: 10.1183/09059180. 00005312.
  18. Simonneau G., Gatzolis G., Adatia I. et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D35–D41. DOI: 10.1016/j.jacc. 2013.10.029.
  19. Humbert M., Sitbon O., Yaici A. et al. Survival in incident and prevalent cohort of patients with pulmonary arterial hypertension.Eur. Respir. J. 2010; 36 (3): 549–555. DOI: 10.1183/ 09031936.00057010.
  20. GaliéN., Hoeper M., Torbicki A. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2009; 30 (20): 2493– 2537. DOI: 10.1093/eurheartj/ehr046.
  21. Nickel N., Golpon H., Greer M. et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension.Eur. Respir. J.2012; 39 (3): 589–596. DOI: 10.1183/09031936.00092311.
  22. Soubrier F., Chung W.K., Machado R. et al. Genetics and genomics of pulmonary arterial hypertension.J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D13–D21. DOI: 10.1016/j.jacc. 2013.10.035.
  23. Eyries M., Montani D., Girerd B. et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension.Nat. Genet. 2014; 46 (1): 65–69. DOI: 10.1038/ng.2844.
  24. D’Alto M., Mahadevan V.S. Pulmonary arterial hypertension associated with congenital heart disease. Eur. Respir. Rev. 2012; 21(126): 328–337. DOI: 10.1183/09059180. 00004712.
  25. Huang J.B., Liang J., Zhou L.Y. Eisenmenger Syndrome: Not Always Inoperable. Respir. Care.2012; 57 (9): 1488–1495. DOI: 10.4187/respcare.01418.
  26. Rubin L.J., Badesch D.B. Evaluation and management of the patient with pulmonary arterial hypertension. Ann. Intern. Med. 2005; 143 (4): 282–292. DOI: 10.7326/0003-4819-143-4200508160-00009.
  27. GaliéN., Rubin L.J. Introduction: new insights into a challenging disease: A review of the third world symposium on pulПульмонология. 2017; 27 (2): 216–231. DOI: 10.18093/086930189320173273232163231 monary arterial hypertension. Am. Coll. Cardiol. J. 2004; 43 (12): S1. DOI: 10.1016/j.jacc.2004.03.003. 45. McGoon M.D. The assessment of pulmonary hypertension. Clin. Chest Med.2001; 22 (3): 493–508. 46. McLaughlin V.V., McGoon M.D. Pulmonary arterial hypertension. Circulation.2006; 114 (13): 1417–1431. DOI: 10.1161/ CIRCULATIONAHA.104.503540. 47. Trip P., Nossent E.J., de Man F.S. et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur. Respir. J. 2013; 42 (6): 1575
  28. GaliéN., Torbicki A., Barst R. et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart. J. 2004; 25 (24): 2243–2278. DOI: 10.1016/ j.ehj.2004. 09.014.
  29. Hambly N., Alawfi F., Mehta S. Pulmonary hypertension: diagnostic approach and optimal management. CMAJ. 2016; 188 (11): 804–812. DOI: 10.1503/cmaj.151075.
  30. McLaughlin V.V., Archer S.L., Badesch D.B. et al. ACCF/ AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009; 119 (16): 2250–2294. DOI: 10.1161/CIRCULATIONAHA. 109.192230.
  31. Lowe B.S., Therrien J., Ionescu-Ittu R. et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes.J. Am. Coll. Cardiol. 2011; 58 (5): 538–546. DOI: 10.1016/j.jacc.2011.03.033.
  32. Humbert M., Sitbon O., Chaouat A. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation.2010; 122 (2): 156–163. DOI: 10.1161/CIRCULATIONAHA.109.911818.
  33. Humbert M., Sitbon O., Yaici A. et al. Survival in incident and prevalent cohort of patients with pulmonary arterial hypertension. Eur. Respir. J.2010; 36 (3): 549–555. DOI: 10.1183/ 09031936.00057010.
  34. Stenmark K.R., Davie N., Frid M. et al. Role of the adventitia in pulmonary vascular remodeling. Physiology(Bethesda). 2006; 21 (2): 134–145. DOI: 10.1152/physiol. 00053.2005.
  35. GaliéN., Manes A., Branzi A. New insights on pulmonary arterial hypertension. Rev. Esp. Cardiol.2004; 57 (7): 603– 607. DOI: 10.1016/S1885-5857(06)60282-X.
  36. Duong-Quy S. Physiopathology of pulmonary hypertension: from bio-molecular mechanism to target treatment. J. Vasc. Med. Surg. 2016; 22 (4): 294–299. DOI: 10.4172/2329-6925. 1000294.
  37. Duplain H., Burcelin R., Sartori C. et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001; 104 (3): 342–345. DOI: 10.1161/01.CIR.104.3.342.
  38. Barst R.J., McGoon M., Torbicki A. et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.2004; 43 (12, Suppl.): S40–S47. DOI: 10.1016/ j.jacc.2004.02.032. http://journal.pulmonology.ru/pulm